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Abstract: Background: Ovarian cancer is the deadliest gynecologic malignancy despite current first-
line treatment with a platinum and taxane doublet. Artesunate has broad antineoplastic properties but
has not been investigated in combination with carboplatin and paclitaxel for ovarian cancer treatment.
Methods: Standard cell culture technique with commercially available ovarian cancer cell lines were
utilized in cell viability, DNA damage, and cell cycle progression assays to qualify and quantify
artesunate treatment effects. Additionally, the sequence of administering artesunate in combination
with paclitaxel and carboplatin was determined. The activity of artesunate was also assessed in 3D
organoid models of primary ovarian cancer and RNAseq analysis was utilized to identify genes and
the associated genetic pathways that were differentially regulated in artesunate resistant organoid
models compared to organoids that were sensitive to artesunate. Results: Artesunate treatment
reduces cell viability in 2D and 3D ovarian cancer cell models. Clinically relevant concentrations
of artesunate induce G1 arrest, but do not induce DNA damage. Pathways related to cell cycle
progression, specifically G1/S transition, are upregulated in ovarian organoid models that are
innately more resistant to artesunate compared to more sensitive models. Depending on the sequence
of administration, the addition of artesunate to carboplatin and paclitaxel improves their effectiveness.
Conclusions: Artesunate has preclinical activity in ovarian cancer that merits further investigation to
treat ovarian cancer.
Keywords: artesunate; ovarian cancer; dihydroartemisinin; Artemesia annua; carboplatin; paclitaxel
1. Introduction
The American Cancer Society estimates 21,410 new cases of ovarian cancer in the
United States in 2021 [1]. Ovarian cancer accounts for only 1.2% of all new cancer cases
but will result in 2.3% of all cancer deaths. With a 5-year overall survival of less than
50%, ovarian cancer is the deadliest gynecologic malignancy. Despite these grim statistics,
there has been little improvement in patient outcomes since the early 2000s. Gynecologic
Oncology Group (GOG) study 111 first showed improved survival with paclitaxel and
cisplatin versus cyclophosphamide and cisplatin [2]. This was followed by GOG 158, which
demonstrated the equivalence of carboplatin and paclitaxel compared to cisplatin and
paclitaxel with decreased toxicity [3]. Since 2003, the carboplatin and paclitaxel doublet has
been the standard of care for the adjuvant treatment of advanced ovarian cancer. To date,
no trials demonstrate improvement in overall survival with the addition of a third cytotoxic
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agent. In 2004, GOG 182 investigated the standard combination of carboplatin and pacli-
taxel in sequential doublets or triplet regimens with gemcitabine, topotecan, or liposomal
doxorubicin. The results showed no difference in progression-free survival and concluded
that carboplatin and paclitaxel should remain standard of care [4]. Recently, therapeutic
advances incorporating PARP and VEGF inhibitors into upfront and maintenance therapy
show promising results in BRCA-mutated and other homologous recombination deficiency
(HRD) cancers [5,6], but only 10–14% of women with epithelial ovarian cancer have a
germline mutation in BRCA1 or 2 [7]. Furthermore, up to 80% of patients with advanced
ovarian cancer who undergo a combination of platinum and taxane-based chemother-
apy will develop recurrence. These outcomes demonstrate the need to identify additional
therapeutic regimens that can be utilized to better treat patients with ovarian cancer.
Artesunate is synthesized from artemisinin, an extract from the sweet wormwood
plant, Artemisia annua [8], and has been used as a fever reducer in Chinese herbal medicine
for over 2000 years. Artesunate is currently a standard, initial treatment for malaria, but has
also been shown to have antineoplastic activity across a broad spectrum of malignancies [9].
It is metabolized to a more active form, dihydroartemisinin (DHA), through plasma es-
terase and hepatic CYP3A4. Both artesunate and DHA are rapidly cleared from the body
with half-lives of approximately 10 min and 1 h, respectively [10]. There are multiple
proposed mechanisms of action by which artesunate eradicates Plasmodium species, in-
cluding generation of free radicals through a heme-iron-dependent mechanism, inhibition
of redox cycling, and interference with Plasmodium sarcoplasmic/endoplasmic calcium
ATPase (SERCA) [8,11,12]. However, there is less consensus on its mechanistic role in
cancer treatment [9,13–18].
Several in vitro studies investigated the effects of artesunate on a wide range of
malignancies. In 2003, the NCI expanded this investigation to a panel of 55 cancer cell lines
that further confirmed artesunate’s in vitro activity across various cancers. Furthermore,
artesunate is unaffected by many of the typical drug resistance pathways [12]. Artesunate
has been shown to have clinical activity in ovarian cancer treatment [15] but has not been
studied in combination with current first-line therapies. In addition to the promising
in vitro studies, artesunate was investigated for safety and tolerability as an addition to
standard chemotherapy regimens, showing early efficacy signals and good tolerability [19].
These findings are reinforced by the numerous malaria trials investigating its safety and
tolerability [10]. Given the significant evidence of in vitro and in vivo activity, we look
to expand the existing preclinical knowledge of artesunate in the treatment of ovarian
cancer [13,20,21]. This study aims to determine the activity and optimal timing of artesunate
in combination with paclitaxel and carboplatin.
2. Materials and Methods
2.1. Cell Culture and Artesunate
Commercially available, human ovarian cancer cell lines UWB1.289 (ATCC CRL-
2945), Caov-3 (ATCC HTB-75), and OVCAR-3 (ATCC HTB-161) were obtained from ATCC.
Cell lines were cultured and maintained in cell line-specific, complete growth media as
recommended by ATCC. All cells were incubated at 37◦C in 5% CO2. Artesunate was
purchased from MedChem Express, dissolved in DMSO as a 200 mM stock solution, and
stored at −80◦C. Artesunate was serially diluted in DMSO, and then media, to the desired
concentrations at the time of each experiment.
2.2. Cell Viability Assays
White-walled 96-well microplates were seeded at 3 × 103 cells per well in 100 µL
growth media and incubated for 24 h at 37◦C, 5% CO2. The growth media was removed
and replaced with fresh media containing serially diluted drugs or drugs of interest. We
tested each drug concentration in duplicate and vehicle (0.1% DMSO) media for control,
in triplicate assays. We used twelve dilutions of the artesunate stock solution, ranging
from 0.0011–200 µM to treat cells and incubated them for 72 h. Cell viability was assessed
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using a CellTiter-Glo 2.0 viability assay (Promega) and luminescence was measured using
a Varioskan LUX multimode microplate reader (ThermoFisher Scientific). We calculated
percent viability by normalizing the relative luminescence signal of each treated well to
the matched vehicle controls. After graphing the calculated percent viability for each
artesunate concentration, a four-parameter log-logistic model was used to fit a non-linear
regression line and the IC50 was calculated for each cell line using GraphPad Prism 5.01.
2.3. 3D Organoids
2.3.1. Tumor Organoid (TO) Development
We collected ovarian tumor tissue from patients after written informed consent at
the time of debulking surgery per the University of Kentucky Institutional Review Board.
These samples were then dissociated and established in Matrigel® Growth Factor Re-
duced Basement Membrane Matrix (Corning) in vitro using factor-defined media and
standard growth conditions [22,23]. Representative sections of TOs were H&E stained
and compared with the primary tumor. Growth and testing of the organoids were done
in a commercial laboratory, Tempus Labs. Mutational concordance was performed by
comparison of sequencing results between the primary tumor specimen and the resultant
tumor organoids.
2.3.2. Chemosensitivity Screens
Established TOs were enzymatically dissociated into single cells and plated in 384-well
plates. The cells were cultured for 72 h before administering artesunate at different doses
(0, 50 nM, 500 nM, 5 µM, and 50 µM). After culturing for an additional 72 h, organoids were
incubated with Hoechst nuclear counterstain and imaged on a spinning disc confocal high
content imager. Once imaging was completed, viability was measured by employing the
MTS assay (Promega). We generated cell viability curves and IC50 values using GraphPad
Prism (v5.01).
2.3.3. Gene Expression Analysis
We extracted total RNA from primary ovarian cancer cell lines used in the develop-
ment of the 3D organoids with RNeasy Plus Universal Mini Kit (Qiagen) followed by full-
whole transcriptome sequencing. We used TruSeq Stranded Total RNA Prep Kit (Illumina)
to generate libraries sequenced as 100 base pairs, single-end reads via an Illumina HiSeq
platform. For all subsequent analysis, the organoid models were divided into two groups
based on their sensitivity to artesunate; the sensitive group consisted of 4 models (2238,
2326, 1236, and 1267) which each had IC50s for artesunate of less than 100 nM, while the
resistant group consisted of two models (1226 and 1254) which had IC50 values greater
than 2 µM. The raw counts, generated from the Illumina HiSeq platform, of the samples
in comparison were first normalized within samples using counts per gene per million
mapped reads (CPM). We excluded from the analysis genes that were unexpressed or
lowly expressed (no sample with CPM > 1). The read counts were further normalized
between samples using TMM (Trimmed Means of M values) to account for the library
size variance. We fit the read counts to a negative binomial distribution model to estimate
variance and used the R software package, edgeR Normalization, for expression modeling
and difference testing [24]. The package applies the negative binomial distribution model
to detect differentially expressed genes in the RNAseq data and calculate a statistical
p-value. The false discovery rate (FDR) was used to adjust for multiple comparisons. The
unsupervised hierarchical clustering analysis and corresponding heatmap were conducted
using the agglomeration method via function heatmap.2 from the R package gplots [25].
Subsequent pathway analysis for differentially expressed genes was conducted using the
goana function from the R package limma [26]. This analysis, which performs gene cate-
gory over-representation analysis on differentially expressed genes incorporating the effect
of selection bias from transcript length, was used to identify cellular pathways which were
either up or downregulated in the artesunate-resistant organoid models when compared to
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the sensitive models. A multiple comparison correction was not performed on the p-values
of the identified differentially expressed pathways.
2.4. DNA Damage Assay
Caov-3 cells were seeded into black-walled µClear 96-well plates at a density of
4000 cells per well in 100 µL of complete growth media and allowed to adhere for 24 h at
37 ◦C with 5% CO2. The media was removed and replaced with complete media containing
5 µM, 10 µM, 50 µM, or 100 µM artesunate, 0.1% DMSO as a negative control, or 25 µM
cisplatin as a positive control. Cells were incubated with drugs for 48 h and then fixed
for 15 min at room temperature in 4% paraformaldehyde. We used 0.25% Triton X-100 to
permeabilize the cells for 15 min and then blocked in 0.1% bovine serum albumin (BSA) for
one hour. We assessed DNA damage with immunofluorescent staining for phosphorylated
histone H2AX (pH2AX) using the HCS DNA Damage Kit (Invitrogen). We used the Cell-
Insight CX7 High Content Analysis Platform for imaging and HCS Studio software to
quantify the nuclear pH2AX signal (both ThermoScientific). We completed the statistical
analysis of pH2AX signal on GraphPad Prism (version 5.01).
2.5. Flow Cytometric Analysis of Cell Cycle
We propagated UWB1 and Caov-3 cells in culture flasks under standard cell culture
conditions outlined above. For the staining solution, 2 mg DNase-free Rnase A (Sigma) and
200 µL of 1 mg/mL propidium iodide were added to 10 mL of 0.1% (v/v) Triton X-100 in
PBS. Treatment media was made by serially diluting stock 200 µM artesunate solutions into
cell line-specific media on the day of treatment. Once cells cultures reached confluence, we
removed the growth media from the treatment flask and added the artesunate treatment
media at a concentration of 10 µM. Cells were collected after 24 or 48 h, washed in PBS, and
resuspended in 0.5 mL PBS before transferring to tubes containing 4.5 mL 70% EtOH for
fixation. Cells were fixed at least overnight at −20◦C. Fixed cells were washed in PBS and
resuspended in 1 mL of staining solution. We sorted the propidium iodide stained cells
with the LSR II cell analyzer. We performed the analysis with ModFit LT v3.3 software.
Statistical analysis comparing the percentage of cells in each phase of the cell cycle (G1, S,
or G2) was performed using GraphPad Prism (version 5.01).
2.6. Drug Administration Sequence Assay
In a similar fashion to the protocols mentioned above in Section 2.2, we plated cells
in a standard 96-well plate at a cell density of 3000 cells/100 µL and incubated for 24 h.
We diluted artesunate, carboplatin, and paclitaxel stock solutions with DMSO and media
to achieve a final concentration of 40 µM, 16 µM, and 32 µM, respectively. Each drug
was added, as indicated, for 24 h and treatment media were then replaced with fresh
media. Drug administration sequences were artesunate on day 1 (D1A) or day 2 (D2A),
carboplatin and paclitaxel on day 2 (D2C/T), carboplatin, paclitaxel, and artesunate on
day 2 (D2C/T/A), or artesunate on day 1 followed by carboplatin and paclitaxel on
day 2 (D1A; D2C/T). Cells were incubated at standard growth conditions for a total of
72 h. Viability measurements were determined using the CellTiter-Glo 2.0 viability assay
(Promega). Luminescence was measured using a Varioskan LUX multimode microplate
reader (ThermoFisher Scientific). Statistical analysis was performed using GraphPad Prism
(v5.01).
3. Results
3.1. Artesunate Has Antineoplastic Activity in Ovarian Cancer
To evaluate the antineoplastic activity of artesunate in ovarian cancer, we assessed the
dose-dependent effect of artesunate on the viability of three epithelial ovarian cancer cell
lines: Caov-3 (adenocarcinoma), UWB1.289 (high-grade serous carcinoma with a BRCA1
mutation), and OVCAR-3 (adenocarcinoma) using the CellTiter-Glo 2.0 assay. The IC50
of artesunate in all three cell lines was in the low to mid micromolar range (Figure 1);
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specifically, the IC50 was 26.91 µM (95% confidence interval 6.287–115.2 µM) in UWB1,
15.17 µM (10.49–21.93 µM) in Caov-3, and 4.67 µM (3.280–6.638 µM) in OVCAR-3 cells. A
One-way ANOVA analysis showed no significant difference (p > 0.05) in the IC50 between
these three cell lines. The IC50 detected for all three ovarian cancer cell lines tested is
consistent with previously established findings [15] and within range of therapeutically
achievable in vivo plasma concentrations (approximately 20 µM) [14,21].
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Figure 1. Artesunate sensitivities across 3 commercially available ovarian cancer cell lines and 6 novel
3D ov rian cancer organoids. (a) Human ovarian cance cell line Caov-3, OVCAR-3, and UWB1.289
cells were treated with serially diluted concentrations of artesunate for 72 h. CellTiter-Glo 2.0 viability
as ay (Promega) was us d to calculate percent viability from the proliferation of treated versus vehicle-
treated control cells. The mean +/− SD from three independent experiments is shown graphically and
IC50s were calculated using a variable slope non-linear regression line. (b) The mean IC50 of artesunate
treatments in each cell line is graphed with SD. Utilizing a one-way ANOVA with Bonferroni’ Multiple
Comparison Test, all IC50s were not significantly different with p > 0.05. (c) 3D ovarian organoids were
established from 6 patients and were treated similarly with serially diluted concentrations of artesunate
for 72 h. Viability was measured with MTS assay (Promega) and the signal for each drug treatment was
normalized to a matched vehicle-treated control. The mean % viability +/− SD is shown graphically
and IC50s were calculated using a variable slope non-linear regression line.
In addition to assessing the sensitivity of established ovarian cancer cell lines to arte-
sunate, we also treated a panel of six primary serous ovarian cancer organoids with increas-
ing doses of artesunate and assessed cell viability using an MTS assay. Two of the organoid
lines, 1226 and 1254, had relatively high IC50 values of 4.478 µM (367.3 nM–54.48 µM) and
2.72 µM (1.564–4.757 µM), respectively (Figure 1c). The other 4 lines were more sensi-
tive to artesunate with IC50 values in the nanomolar range as follows: 2238 = 89.53 nM
(40.63–197.3 nM), 2326 = 62.55 nM (5.359–730.1 nM), 1236 = 17.42 nM (1.345–225.5 nM),
and 1267= 9.22 nM (0.8596–98.94 nM). The IC50 values calculated for all six serous ovar-
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ian cancer organoid models fall within the range of therapeutically achievable plasma
concentrations.
3.2. RNAseq Analysis Comparing Resistant and Sensitive Organoids
RNAseq analysis was performed on untreated primary organoid ovarian cancer cell
lines. After stratifying the cell lines into sensitive (2238, 2326, 1236, 1267) or resistant (1226
and 1254) based on their IC50 values, analysis revealed 1042 genes differentially expressed
between the two groups of organoid models (Table S1). A heatmap was generated for
the top 26 most significantly differentiated genes between these two groups (Figure 2).
These genes were further interrogated in the Edge software package to reveal 588 path-
ways significantly upregulated in the resistant organoid models versus 211 pathways that
were downregulated. Table 1 lists a subset of 38 pathways of interest for artesunate use in
cancer and indicates which of the differentially expressed genes are associated with each
pathway [8,11,12,15,20,27]. These 38 pathways of interest contain 8 genes with increased
expression and 2 genes with decreased expression in the resistant organoid group. All of
the 10 genes identified in these pathways are among the most significantly differentially
expressed genes seen in Figure 2. The false discovery rate (FDR) was used to adjust for
multiple comparisons in the RNAseq analysis. A multiple comparison correction was
not performed on the p-values of the identified differentially expressed pathways. In the
artesunate-resistant organoids, pathways involved in the cellular response to oxidative
stress were upregulated, while pathways that negatively regulate oxidative phosphory-
lation and mitochondrial function were downregulated. Additionally, pathways related
to cell cycle progression, specifically G1/S transition, were upregulated in the ovarian
organoid models more resistant to artesunate.
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Table 1. Pathway analysis of genes differentially expressed between the resistant (1226 and 1254) and sensitive (2238, 2326,
1236, 1267) organoid models. Gene ontology IDs are listed under pathway ID.
General Category Pathway ID Pathway Description p-Value DifferentiallyExpressed Genes
ROS/oxidative
phosphorylation
GO:0000302 response to reactive oxygenspecies ↑ 0.0008
↑ AQP1, ↑ CRYAB, ↑
EGFR
GO:0006979 response to oxidative stress ↑ 0.0056 ↑ AQP1, ↑ CRYAB, ↑EGFR
GO:0034614 cellular response to reactiveoxygen species ↑ 0.0077 ↑ AQP1, ↑ EGFR
GO:2000377 regulation of reactive oxygenspecies metabolic process ↑ 0.0098 ↑ CRYAB, ↑ EGFR
GO:0072593 reactive oxygen species metabolicprocess ↑ 0.0212 ↑ CRYAB, ↑ EGFR
GO:0034599 cellular response to oxidativestress ↑ 0.0241 ↑ AQP1, ↑ EGFR
GO:2000378 negative regulation of reactiveoxygen species metabolic process ↑ 0.045 ↑ CRYAB
GO:0090324 negative regulation of oxidativephosphorylation ↓ 0.0018 ↓ DNAJC15
GO:0002082 regulation of oxidativephosphorylation ↓ 0.0074 ↓ DNAJC15













↓ 0.0005 ↓ DNAJC15
GO:1901856 negative regulation of cellularrespiration ↓ 0.0010 ↓ DNAJC15
GO:1902956
regulation of mitochondrial
electron transport, NADH to
ubiquinone
↓ 0.0013 ↓ DNAJC15
GO:1905446
regulation of mitochondrial ATP
synthesis coupled electron
transport
↓ 0.0018 ↓ DNAJC15
GO:0005744 TIM23 mitochondrial import innermembrane translocase complex ↓ 0.0036 ↓ DNAJC15
GO:0043457 regulation of cellular respiration ↓ 0.0076 ↓ DNAJC15
GO:0006120 mitochondrial electron transport,NADH to ubiquinone ↓ 0.0135 ↓ DNAJC15
GO:0042775 mitochondrial ATP synthesiscoupled electron transport ↓ 0.0235 ↓ DNAJC15
GO:0042773 ATP synthesis coupled electrontransport ↓ 0.0238 ↓ DNAJC15
GO:0006626 protein targeting to mitochondrion ↓ 0.0248 ↓ DNAJC15
GO:1990542 mitochondrial transmembranetransport ↓ 0.0255 ↓ DNAJC15
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Table 1. Pathway analysis of genes differentially expressed between the resistant (1226 and 1254) and sensitive (2238, 2326,
1236, 1267) organoid models. Gene ontology IDs are listed under pathway ID.




GO:0022904 respiratory electron transportchain ↓ 0.0285 ↓ DNAJC15
GO:0098800 inner mitochondrial membraneprotein complex ↓ 0.0332 ↓ DNAJC15
GO:0072655 establishment of proteinlocalization to mitochondrion ↓ 0.0345 ↓ DNAJC15
GO:0045333 cellular respiration ↓ 0.0473 ↓ DNAJC15
cell cycle progression
GO:1900087 positive regulation of G1/Stransition of mitotic cell cycle ↑ 0.0302 ↑ EGFR
GO:0045740 positive regulation of DNAreplication ↑ 0.0302 ↑ EGFR
GO:1902808 positive regulation of cell cycleG1/S phase transition ↑ 0.0384 ↑ EGFR
GO:0045787 positive regulation of cell cycle ↑ 0.0391 ↑ SMOC2, ↑ EGFR, ↓MEIS2
response to metal ion
GO:0010038 response to metal ion ↑ 0.0034 ↑ AQP1, ↑MT1A, ↑EGFR
GO:0071248 cellular response to metal ion ↑ 0.0005 ↑ AQP1, ↑MT1A, ↑EGFR
Cell death/apoptosis GO:0060548 negative regulation of cell death ↑ 0.0011
↑ AQP1, ↑ GABRB3, ↑
CD200,↑ CRYAB, ↑
EGFR
GO:0043067 regulation of programmed celldeath ↑ 0.0375
↑ AQP1, ↑ GABRB3, ↑
CRYAB,↑ EGFR
ATP metabolic process
GO:1903579 negative regulation of ATPmetabolic process ↓ 0.0064 ↓ DNAJC15
GO:1903578 regulation of ATP metabolicprocess ↓ 0.0300 ↓ DNAJC15
response to




signaling ↑ 0.0097 ↑ RELN, ↑ EGFR
↑: indicates upregulation of pathway or increased gene expression in artesunate-resistant organoid models; ↓: indicates downregulation of
pathway or decreased gene expression in artesunate-resistant organoid models.
3.3. Clinically Relevant Concentrations of Artesunate Induce G1 Arrest, but Not DNA Damage
After showing that artesunate can reduce cell viability in ovarian cancer cells, we
explored potential resistance mechanisms using the pathway analysis from RNAseq com-
paring artesunate-sensitive and -resistant organoid models. Previously published findings
from multiple cancer types have implicated several mechanisms of action of artesunate,
including increased reactive oxygen species (ROS) that can induce DNA damage and cell
cycle arrest [15,17,28]. Caov-3 cells are used because of their close correlation to IC50s
previously published as well as their known platinum sensitivity which correlates to most
high-grade serous ovarian cancers [15,29]. To assess the ability of artesunate to induce
DNA damage in Caov-3 cells, we quantified the immunofluorescent staining for pH2AX,
a marker of double-strand breaks, following a 48 hr treatment with concentrations of
artesunate ranging from 5–100 µM and 25 µM cisplatin as a positive control (Figure 3).
Cells treated with 0.1% DMSO as a control had a mean pH2AX signal of 443.2 +/− 76.38,
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while treatment with 25 µM cisplatin resulted in a mean signal of 2517 +/− 230.4. The only
artesunate treatment that significantly increased DNA damage was 100 µM artesunate
with a mean pH2AX signal of 617.0 +/− 31.96. Treatment with 5, 10, or 50 µM resulted in
pH2AX measurements of 382.8 +/− 39.58, 370.2 +/− 9.283, and 393.8 +/− 58.79, respec-
tively. Only the highest concentration of artesunate (100 µM) and cisplatin resulted in a
significant increase in DNA damage compared to vehicle-treated control cells as assessed
by a one-tailed unpaired t-testuprho (p = 0.0486 for 100 µM artesunate and p = 0.0034 for 25
µM cisplatin). Therefore, while artesunate was able to induce DNA damage, as previously
reported [4], we did not observe this effect at clinically relevant concentrations in Caov-3
cells and did not pursue this further in additional cell lines.




Figure 3. DNA damage assay as average nuclear pH2AX intensity. (a) The average nuclear intensity of pH2AX staining 
was quantified in Caov-3 cells treated for 48 h with artesunate concentrations ranging from 5–100μM with 25 μM cisplatin 
treatment as a positive control. The mean signal +/− SD was graphed and a one-tailed t-test was performed (* p = 0.0486, 
** p = 0.0034) (b) Representative images of cells treated with 0.1% DMSO (vehicle), 10 μM artesunate, 100 μM artesunate, 
or 25 μM cisplatin (positive control for DNA damage). 
The second mechanism of action for artesunate we investigated was the induction of 
cell cycle arrest. We assessed cell cycle progression by propidium iodide staining and flow 
cytometry of Caov-3 and UWB1 cells following treatment with 10 μM artesunate or 0.1% 
DMSO (vehicle control) for 24 and 48 h. Representative histogram images of the propid-
ium iodide staining and overlaid cell cycle analysis are in Supplemental Figure 1 (Caov-
3) and Supplemental Figure 2 (UWB-1). The percentages of cells in G1 and S phase with 
and without 10 μM artesunate treatment were determined from three independent exper-
iments. In Caov-3 cells, 48-h artesunate treatment resulted in an increased percentage of 
cells in G1 (78.98% +/− 0.9546 compared to 61.23% +/− 1.789 in vehicle-treated cells). UWB1 
cells had 65.35% +/− 0.0849 cells in G1 after artesunate treatment compared to 60.35% +/− 
2.418 of control cells (Figure 4a,b). Both cell lines showed a significant increase in cells in 
G1 (p = 0.0032 in Caov-3 and p = 0.0499 in UWB1; one-tailed unpaired t-test). In a further 
subgroup analysis, the increased percentage of Caov-3 and UWB1 cells in the G1 phase 
following treatment with artesunate was accompanied by a significant decrease in cells in 
the S phase (p = 0.0009 and p = 0.0497, respectively). In Caov-3 cells, 48-h artesunate treat-
ment resulted in a decreased percentage of cells in S phase (12.14% +/− 0.1556 compared 
to 24.42% +/− 0.7354 in vehicle-treated cells). UWB1 cells had 18.87% +/− 2.779 cells in S 
phase after artesunate treatment compared to 26.25% +/− 2.234 of control cells (Figure 
4c,d). These experiments demonstrate that in the cell lines tested, clinically relevant con-
centrations of artesunate induce G1 arrest but not DNA damage. 
Figure 3. DNA damage assay as average nuclear pH2AX intensity. (a) The average nuclear intensity of pH2AX staining
was quantified in Caov-3 cells treated for 48 h with artesunate concentrations ranging from 5–100 µM with 25 µM cisplatin
treatment as a positive control. The mean signal +/− SD was graphed and a one-tailed t-test was performed (* p = 0.0486,
** p = 0.0034) (b) Representative images of cells treated with 0.1% DMSO (vehicle), 10 µM artesunate, 100 µM artesunate, or
25 µM cisplatin (positive control for DNA damage).
The second mechanism of action for artesunate we investigated was the induction
of cell cycle arrest. We assessed cell cycle progression by propidium iodide staining and
flow cytometry of Caov-3 and UWB1 cells following treatment with 10 µM artesunate or
0.1% DMSO (vehicle control) for 24 and 48 h. Representative histogram images of the
propidium iodide staining and overlaid cell cycle analysis are in Figure S1 (Caov-3) and
Figure S2 (UWB-1). The percentages of cells in G1 and S phase with and without 10 µM
artesunate treatment were determined from three independent experiments. In Caov-3
cells, 48-h artesunate treatment resulted in an increased percentage of cells in G1 (78.98%
+/− 0.9546 compared to 61.23% +/− 1.789 in vehicle-treated cells). UWB1 cells had 65.35%
+/− 0.0849 cells in G1 after artesunate treatment compared to 60.35% +/− 2.418 of control
cells (Figure 4a,b). Both cell lines showed a significant increase in cells in G1 (p = 0.0032 in
Caov-3 and p = 0.0499 in UWB1; one-tailed unpaired t-testuprho). In a further subgroup
analysis, the increased percentage of Caov-3 and UWB1 cells in the G1 phase following
treatment with artesunate was accompanied by a significant decrease in cells in the S phase
(p = 0.0009 and p = 0.0497, respectively). In Caov-3 cells, 48-h artesunate treatment resulted
in a decreased percentage of cells in S phase (12.14% +/− 0.1556 compared to 24.42% +/−
0.7354 in vehicle-treated cells). UWB1 cells had 18.87% +/− 2.779 cells in S phase after
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artesunate treatment compared to 26.25% +/− 2.234 of control cells (Figure 4c,d). These
experiments demonstrate that in the cell lines tested, clinically relevant concentrations of
artesunate induce G1 arrest but not DNA damage.




Figure 4. Cell cycle analysis using propidium iodide staining. The percentage of Caov-3 and UWB1 cells in G1 after 24 h 
(a) or 48 h (b) treatment with 0.1% DMSO (control) or 10 μM artesunate is graphed as the mean +/− SD from three inde-
pendent experiments. A one-tailed unpaired t-test revealed a statistically significant increase in cells in G1 in UWB1 cells 
treated for either 24 or 48 h (* p < 0.05) and in Caov-3 cells treated with artesunate for 48 h (** p < 0.01). The concurrent 
analysis of the percentage of cells in S phase following 24 (c) or 48 (d) hour treatment with artesunate reveals a significant 
decrease in cells in S phase after 48 h (* p < 0.05; *** p < 0.001). 
3.4. Addition of Artesunate to Carboplatin and Paclitaxel Improves Antineoplastic Activity 
The current primary treatment regimen in ovarian cancer is a platinum/taxane dou-
blet, such as carboplatin and paclitaxel. The favorable side effect profile and its effects on 
cell viability make artesunate a possible addition to the current standard of care regimen. 
Therefore, we next assessed the effect of adding artesunate to cells treated with both 
paclitaxel and carboplatin. Since artesunate induces cell cycle arrest in the G1 phase, we 
evaluated artesunate as either a pretreatment (24 h prior) or concurrently with carboplatin 
and paclitaxel. In both cell lines, treatment with artesunate alone on either day 1 or day 2 
resulted in a decreased cell viability to 54.60–63.43% compared to vehicle-treated control 
cells (Figure 5). In Caov-3 cells, treatment with carboplatin/paclitaxel resulted in reduced 
cell viability to 29.60% +/− 7.780, which was significantly decreased when artesunate was 
added concurrently (11.55% +/− 5.917, p < 0.05 One-way ANOVA) but not when cells were 
pretreated with artesunate (33.16% +/− 3.349, p > 0.005). Similarly, in UWB1, cell viability 
was decreased to 62.06% +/− 9.389 when treated with carboplatin and paclitaxel, which 
was further decreased to 39.65% +/− 6.850 (p < 0.05, One-way ANOVA) with the concur-
rent addition of 40 μM artesunate. In these cells, pretreatment with artesunate resulted in 
cell viability of 56.41% +/− 2.148, which was not statistically significant when compared to 
cells treated with carboplatin and paclitaxel. Given that carboplatin works in the S phase 
and paclitaxel in the M phase, it is not surprising that pretreatment with artesunate, which 
causes G1 arrest, did not improve the regimen’s effectiveness while concurrent admin-
istration did. Future clinical studies should consider concurrent administration of the 
three medications. 
Figure 4. ell cycle analysis using propidium iodide staining. The percentage of Caov-3 and UWB1 cells in G1 after 24 h (a)
or 48 h (b) treatment with 0.1% DMSO (control) or 10 µM artesunate is graphed as the mean +/− SD from three independent
experiments. A one-tailed unpaired t-testuprho revealed a statistically significant increase in cells in G1 in UWB1 cells
treated for either 24 or 48 h (* p < 0.05) and in Caov-3 cells treated with artesunate for 48 h (** p < 0.01). The concurrent
analysis of the percentage of cells in S phase following 24 (c) or 48 (d) hour treatment with artesunate reveals a significant
decrease in cells in S phase after 48 h (* p < 0.05; *** p < 0.001).
3.4. Addition of Artesunate to Carboplatin and Paclitaxel Improves Antineoplastic Activity
The current primary treatment regimen in ovarian cancer is a platinum/taxane dou-
blet, such as carboplatin and paclitaxel. The favorable side effect profile and its effects
on cell viability make artesunate a possible addition to the current standard of care regi-
men. Therefore, we next assessed the effect of adding artesunate to cells treated with both
paclitaxel and carboplatin. Since artesunate induces cell cycle arrest in the G1 phase, we
evaluated artesunate as either a pretreatment (24 h prior) or concurrently with carboplatin
and paclitaxel. In both cell lines, treatment with artesunate alone on either day 1 or day 2
resulted in a decreased cell viability to 54.60–63.43% compared to vehicle-treated control
cells (Figure 5). In Caov-3 cells, treatment with carboplatin/paclitaxel resulted in reduced
cell viability to 29.60% +/− 7.780, which was significantly decreased when artesunate was
added concurrently (11.55% +/− 5.917, p < 0.05 One-way ANOVA) but not when cells were
pretreated with artesunate (33.16% +/− 3.349, p > 0.005). Similarly, in U B1, cell viability
as decreased to 62.06 +/ 9.389 when treated ith carboplatin and paclitaxel, hich
as further decreased to 39.65 +/− 6.850 (p < 0.05, One-way ANOVA) with the concur-
rent a ition of 40 µ artes nate. In these cells, retreat ent ith artes nate res lte in
cell ia ilit of 56.41 +/− 2.148, which was not statistically significant when compared
to cells tr ated with carboplatin and p clitaxel. Given that carboplatin works in t e S
phase and paclitax l in t e M phase, it is not surprising that pretreatment with rtesunate,
which causes G1 arrest, did n t improve th regimen’s effectiveness while concurre t
administration did. Future clinical studies should consider concurrent administration of
t e thre medications.
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Figure 5. Drug Administration Sequence Assay for artesunate, carboplatin, and paclitaxel. Cells were treated with ar-
tesunate on day 1 (D1A) or day 2 (D2A), carboplatin and paclitaxel on day 2 (D2C/T), carboplatin, paclitaxel, and ar-
tesunate on day 2 (D2C/T/A), or artesunate on day 1 followed by carboplatin and paclitaxel on day 2 (D1A; D2C/T). The 
24 h treatment concentrations for artesunate, carboplatin, and paclitaxel were 40 μM, 16 μM, and 32 μM, respectively. 
Percent viability was calculated utilizing the CellTiter-Glo 2.0 viability assay following treatment with car-
boplatin/paclitaxel and/or artesunate compared to DMSO-treated (control) cells, as indicated, shown graphically as the 
mean +/− SD in Caov-3 (a) and UWB1 (b) cells. Statistical differences were assessed by One-way ANOVA (ns—not signif-
icant and * p < 0.05). In both cell lines, the addition of artesunate as a concurrent treatment with carboplatin/paclitaxel 
resulted in a significant decrease in viable cells. 
4. Discussion 
The discovery of artemisinin as an anti-malarial compound in 1967 was a significant 
medical advance, with Tu Youyou being awarded the Nobel prize in 2015 for this same 
discovery [11]. Our understanding of its physical and biochemical properties over the last 
half-century has led to the development of artesunate as a successful malaria treatment. 
This safe and well-tolerated medicine has also shown promising antineoplastic activity 
across several cancer types. Efferth and colleagues demonstrated in vitro activity across a 
panel of 50 established cancer cell lines while also defining several of the molecular modes 
of action [12]. In this study, which is consistent with other published reports 
[9,15,20,21,27,28,30,31], we demonstrate that artesunate inhibits cell viability with IC50 
values in the micromolar range across a panel of ovarian cancer cell lines. Additionally, 
several patient-derived 3D tumor organoids, a more accurate model of in vivo tumor bi-
ology with the potential to correlate in vivo and in vitro chemotherapy sensitivities, were 
even more sensitive to artesunate with IC50 values ranging from 9.22 nM–4.478 μM (Fig-
ure 1c) [32]. These concentrations are achievable clinically, with one study of adults with 
severe malaria receiving a 2.4 mg/kg dose of artesunate twice a day demonstraiting a 
Cmax of approximately 3200 ng/mL (8.325 μM) [10], which is also consistent with concen-
trations found in a phase 1 trial of artesunate in solid tumor malignancies [19]. Encour-
aged by the cytotoxicity demonstrated at clinically achievable doses, we evaluated poten-
tial mechanisms of action of artesunate in ovarian cancer. 
Efferth and colleagues demonstrated that CDC25A protein, which governs G1 cell 
entry into S1, is downregulated with artesunate treatment [12]. Our data showing G1 
phase arrest supports these findings (Figure 4). Furthermore, the Greenshield lab deter-
mined that cell cycle arrest is dose-dependent with G1 phase arrest at concentrations com-
parable to our in vitro data at 10 μM [15]. They also showed G2/M phase arrest at 100 μM 
[15]. Several trends in differential expression of mRNA in artesunate-resistant organoids 
support these previously proposed mechanisms and are consistent with genes identified 
5. rug Administration Sequence Assay for artesunate, carboplatin, and paclitaxel. Cel s w re treat d with artesun te
on day 1 (D1A) or day 2 (D2A), carboplatin and paclitaxel on day 2 (D2C/T), carboplatin, paclitaxel, and artesunate on day
2 (D2C/T/A), or artesunate on day 1 followed by carboplatin and paclitaxel on day 2 (D1A; D2C/T). The 24 h treatment
concentrations for artesunate, carboplatin, and paclitaxel were 40 µM, 16 µM, and 32 µM, respectively. Percent viability was
calculated utilizing the CellTiter-Glo 2.0 viability assay following treatment with carboplatin/paclitaxel and/or artesunate
compared to DMSO-treated (control) cells, as indicated, shown graphically as the mean +/− SD in Caov-3 (a) and UWB1
(b) cells. Statistical differences were assessed by One-way ANOVA (ns—not significant and * p < 0.05). In both cell lines, the
addition of artesunate as a concurrent treatment with carboplatin/paclitaxel resulted in a significant decrease in viable cells.
4. Discussion
The discovery of artemisinin as an anti-malarial compound in 1967 was a significant
medical advance, with Tu Youyou being awarded the Nobel prize in 2015 for this same
discovery [11]. Our understanding of its physical and biochemical properties over the
last half-century has led to the development of artesunate as a successful malaria treat-
ment. This safe and well-tolerated medicine has also shown promising antineoplastic
activity across several cancer types. Efferth and colleagues demonstrated in vitro activ-
ity across a panel of 50 established cancer cell lines while also defining several of the
molecular modes of action [12]. In this study, which is consistent with other published
reports [9,15,20,21,27,28,30,31], we demonstrate that artesunate inhibits cell viability with
IC50 values in the micromolar range across a panel of ovarian cancer cell lines. Addi-
tionally, several patient-derived 3D tumor organoids, a more accurate model of in vivo
tumor biology with the potential to correlate in vivo and in vitro chemotherapy sensitivities,
were even more sensitive to artesunate with IC50 values ranging from 9.22 nM–4.478 µM
(Figure 1c) [32]. These concentrations are achievable clinically, with one study of adults
with severe malaria receiving a 2.4 mg/kg dose of artesunate twice a day demonstraiting a
Cmax of approximately 3200 ng/mL (8.325 µM) [10], which is also consistent with concen-
trations found in a phase 1 trial of artesunate in solid tumor malignancies [19]. Encouraged
by the cytotoxicity demonstrated at clinically achievable doses, we evaluated potential
mechanisms of action of artesunate in ovarian cancer.
Efferth and colleagues demonstrated that CDC25A protein, which governs G1 cell
entry into S1, is downregulated with artesunate treatment [12]. Our data showing G1 phase
arrest supports these findings (Figure 4). Furthermore, the Greenshield lab determined that
cell cycle arrest is dose-dependent with G1 phase arrest at concentrations comparable to our
in vitro data at 10 µM [15]. They also showed G2/M phase arrest at 100 µM [15]. Several
trends in differential expression of mRNA in artesunate-resistant organoids support these
previously proposed mechanisms and are co sistent with genes identified across a pa el of
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55 different tumor types that correlate with artesunate resistance [12]. Pathways involved
in the cellular response to oxidative stress and G1/S transition are upregulated, while
pathways that negatively regulate oxidative phosphorylation and mitochondrial function
are downregulated (Table 1). Although our lab did not show DNA damage at therapeutic
concentrations of artesunate, other labs have shown it downregulates RAD51 and inhibits
the mTOR pathway [15,21], further sensitizing cells to ROS-induced double-strand break.
While we demonstrate DNA damage at 100 µM concentrations, this was not observed at
lower concentrations. It remains unclear whether artesunate induces ROS at therapeutic
concentrations but genes involved in response to oxidative stress are upregulated in resis-
tant organoid models (Table 1). Other studies have demonstrated that artesunate’s ability
to cause oxidative damage is iron-dependent, due to the endoperoxide bridge in artesunate
interacting with Heme iron-producing cytotoxic radicles [16] This may explain the lack
of ROS at physiologic concentrations observed in iron-poor in vitro systems. Although
artesunate is not affected by most common chemotherapy resistance pathways [12,32],
EGFR expression did correlate with resistance and EGFR expression was upregulated
in the resistant primary organoid models in this study (Figure 2 and Table 1). EGFR is
known to induce expression of Bcl-2 and down-regulates BAX, resulting in inhibition of
apoptosis. Alternatively, artesunate is reported to inhibit phosphorylation of BAD, promot-
ing the formation of BAD/Bcl-xL complex, which triggers the intrinsic apoptotic cascade
involving cytochrome c and may serve as a mechanism for ROS formation-independent
cell death [33]. Therefore, it is reasonable to hypothesize that EGFR overexpression in
artesunate-resistant ovarian cancer cells could impair the ability of artesunate to induce
apoptosis through the BAD/Bcl-xL complex. Additional studies are needed to verify the
role of EGFR overexpression in artesunate resistance and to determine if EGFR inhibitors
could sensitize ovarian cancer models, which would otherwise harbor innate resistance, to
artesunate treatment.
While most of the artesunate safety data are taken from malaria treatment studies
with a short duration of administration, a small study in patients with metastatic breast
cancer showed good safety and tolerability to oral artesunate dosages of up to 200 mg/day
over several years [34]. Anemia and diarrhea are the most common adverse effects. [32,35].
Currently, there are several clinical trials investigating artesunate’s anticancer effects, but
most are early phase [17]. There are no published reports of artesunate outcomes in ovarian
cancer, but one patient with metastatic ovarian cancer was enrolled in an early-phase trial
and had stable disease while receiving eight months of the lowest dose (8 mg/kg) [19].
Although trial designs have varied routes of administration and schedules, intravenous
artesunate treatment has been shown to have an maximum tolerated dose of 18 mg/kg
on a D1/D8, 3 week administration [19] that could be incorporated into standard dosing
schedules of frontline carboplatin and paclitaxel.
The administration schedule of chemotherapies is vitally important when utilizing
multi-drug regimens as many drugs have mechanisms of action that are dependent on
the cell cycle. Taxol has sequence-dependent cytotoxicity. In ovarian cancer, sequential
administration of paclitaxel followed by carboplatin is the standard of care. If carbo-
platin is administered first, there is an antagonistic interaction with paclitaxel that can
be observed along with increased toxicity [35]. Taxol has been reported to have similar
sequence-dependence with etoposide, 5-FU, and several other agents [7]. Furthermore,
since we observed G1 phase arrest with artesunate administration, it was necessary to
learn more about the potential interactions with carboplatin and paclitaxel, which is M
phase-dependent. As anticipated, we saw a decrease in cell viability with coadministration
versus pretreatment with artesunate. This finding should help guide further investigative
efforts in incorporating artesunate into ovarian cancer treatment.
To our knowledge, this is the first paper to describe the increased anticancer effect of
artesunate in combination with carboplatin and paclitaxel in ovarian cancer. Strengths of
this work include the large number of ovarian cell lines and organoids that show the consis-
tent anticancer activity of artesunate, the demonstration of the added activity of artesunate
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in combination with standard therapies, and our RNAseq studies that support the role of
cell cycle arrest and generation of ROS as the primary mechanism of artesunate activity.
Artesunate has been shown to have single-agent activity in a variety of cancer
types [19,34]. The observed activity in ovarian cancer as a single agent in in vitro stud-
ies [15] along with its favorable toxicity profile [10,36] make it a promising candidate to
study in ovarian cancer treatment. Additionally, our research supports further evalua-
tion of artesunate combined with paclitaxel and carboplatin in animal models and future
clinical trials.
Supplementary Materials: The following are available online at https://www.mdpi.com/2075-4
418/11/3/395/s1, Table S1: Significantly differentially expressed genes between the more resistant
(1226 and 1254) and sensitive (2238, 2326, 1236, 1267) organoid models; Figure S1: Representative
flow cytometry histograms of cell cycle analysis for Caov-3 cells treated for 24hr or 48hr with DMSO
control or artesunate; Figure S2: Representative flow cytometry histograms of cell cycle analysis for
UWB1 cells treated for 24hr or 48hr with DMSO control or artesunate.
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